Susvimo is an FDA-approved eye implant for diabetic macular edema that may reduce monthly injections to just two treatments a year while maintaining vision outcomes.

DME is a diabetes complication that threatens your the clarity of your vision. But managing blood sugar, blood pressure, and cholesterol can lower your risk.

Severe, long-standing DME with cystoid changes, subretinal detachment, and high inflammatory cytokine burden tends to respond better to dual ANG2/VEGF-A inhibition than VEGF monotherapy. Faricimab ...

Active Phase 3 programs for DURAVYU in wet AMD and DME, the two largest multi-billion-dollar retinal disease markets –– Topline data for ...

Diabetic macular edema (DME) is an eye condition that can lead to vision loss in people with diabetes. It occurs as a result of diabetic retinopathy — damaged blood vessels in the eyes due to elevated ...

The trials are evaluating DURAVYU (vorolanib intravitreal insert) for the treatment of diabetic macular edema (DME).

Diabetic macular edema (DME) occurs when fluid accumulates behind the macula, the part of your retina that processes central vision. DME can occur at any stage of diabetic retinopathy (DR). However, ...

An estimated 750,000 Americans have diabetic macular edema (DME), a type of vision loss that can occur in people with diabetes, according to the American Academy of Ophthalmology. Caused in part by ...

Diabetes mellitus (DM) is a rapidly growing epidemic in the United States, and it is expected to affect 592 million individuals within the next 20 years. Diabetic retinopathy (DR) and diabetic macular ...

VIS-101, purpose-designed to be a best-in-class dual VEGF-A/ANG-2 inhibitor, has the potential to provide more effective and ...